RxLabelGuard delivers FDA-sourced drug interaction data through a REST API with severity scoring, mechanism details, and evidence citations. Transparent pricing starting at $0/month. No enterprise licensing process required.
Medi-Span is a comprehensive drug database owned by Wolters Kluwer Health. It has been a foundational data source for pharmacy management systems, pharmacy benefit managers (PBMs), and healthcare IT platforms for decades. Medi-Span provides drug pricing data, clinical screening modules, and drug identification databases that power many of the pharmacy and claims processing systems used across the United States.
The Medi-Span Clinical suite includes drug-drug interaction screening, drug-allergy checking, duplicate therapy detection, dose range checking, and drug-disease contraindication screening. These modules are typically embedded into pharmacy dispensing systems, PBM adjudication engines, and electronic prescribing platforms as part of the clinical decision support workflow.
Medi-Span is considered the industry standard for pharmacy and PBM drug data. Its National Drug Code (NDC) database, Average Wholesale Price (AWP) data, and Generic Product Identifier (GPI) classification system are widely adopted across the pharmaceutical supply chain. The drug interaction screening module is one component within this much larger drug data infrastructure.
Recently, Wolters Kluwer launched Medi-Span Expert AI, an MCP (Model Context Protocol) server that enables AI assistants and large language models to access Medi-Span drug data programmatically. This represents Wolters Kluwer's entry into the AI-assisted drug information space, though it remains within the enterprise licensing framework.
Medi-Span licensing is structured for enterprise customers. Pricing is not publicly listed and typically involves a sales process with custom quotes based on the scope of data access, number of modules, deployment model, and transaction volume. For teams that specifically need drug interaction checking via a modern REST API, the full Medi-Span licensing process may be more complex and costly than the use case requires.
Medi-Span licensing is structured for pharmacy chains, PBMs, and large healthcare IT vendors. Startups, smaller development teams, and individual developers building focused applications often find that the minimum licensing commitment exceeds their budget when drug interaction checking is their only requirement.
Medi-Span encompasses drug pricing (AWP), NDC databases, GPI classification, clinical screening modules, and more. When a team specifically needs drug interaction checking with severity scoring and evidence citations, licensing the full Medi-Span data suite introduces cost and complexity for data they will not use.
Medi-Span data is typically delivered as data feeds that customers load into their own databases. This requires infrastructure for data ingestion, refresh scheduling, schema management, and version control. A hosted REST API eliminates this operational overhead for teams that prefer cloud-hosted data access.
There is no public API endpoint where developers can sign up, generate a key, and start querying drug interactions immediately. The procurement process involves contacting Wolters Kluwer sales, evaluating licensing terms, and completing a data licensing agreement.
Development teams building MVPs or evaluating drug data sources need pricing they can include in project budgets without a sales discovery process. Publicly listed pricing tiers with clear request limits allow teams to forecast costs accurately and start building immediately.
Healthcare applications need to demonstrate where drug interaction data originates. Teams want interaction results that include verifiable FDA label references -- SPL Set IDs, label sections, and evidence text -- for compliance documentation and clinical audit trails.
An honest side-by-side comparison to help you evaluate which solution fits your needs.
| Feature | Medi-Span | RxLabelGuard |
|---|---|---|
| Data Source | Proprietary curated database with editorial review and clinical literature references | FDA Structured Product Labeling (public, verifiable) |
| Scope | Full pharmacy data: drug pricing (AWP), NDC database, GPI classification, clinical screening modules | Focused on drug interaction detection with severity scoring and evidence citations |
| Pricing | Enterprise licensing with custom quotes (contact sales, not publicly listed) | Free tier ($0), Developer ($20/mo), Professional ($99/mo) |
| Setup Time | Enterprise sales process: weeks to months (evaluation, data licensing, integration) | Self-service: minutes to first API call |
| Free Tier | No free tier available | Yes -- 50 requests/month on Sandbox plan |
| API / Data Access | Data feeds loaded into customer databases; Expert AI MCP server for AI agent access | Cloud-hosted REST API with JSON responses |
| AI Integration | Medi-Span Expert AI (MCP server) for AI assistants and LLMs | AI-powered extraction pipeline (Bedrock) with standard REST API interface |
| Interaction Output | Severity classification, clinical significance, management recommendations | Severity, mechanism of action, clinical recommendations, evidence citations |
| Evidence Citations | References to clinical literature and pharmacological studies | SPL Set ID + FDA label section + evidence text snippet per interaction |
| Drug Resolution | GPI (Generic Product Identifier), NDC codes, and proprietary identifiers | RxNorm (RxCUI), NDC codes, brand and generic names with fuzzy matching |
| Self-Service Signup | No -- requires enterprise sales process and data licensing agreement | Yes -- create account, generate API key, start testing immediately |
Medi-Span offers substantially broader pharmacy data infrastructure including drug pricing (AWP), NDC databases, GPI classification, and clinical screening modules. Medi-Span Expert AI adds AI-assisted drug data access via MCP. RxLabelGuard focuses specifically on drug interaction detection with FDA-sourced evidence citations and self-service API access.
Three steps from drug names to structured interaction data.
Pass drug names, NDC codes, or RxCUI identifiers to our REST API endpoint. We accept brand names, generic names, and common abbreviations.
Your input is normalized to RxCUI via RxNorm fuzzy matching, then we retrieve the latest FDA Structured Product Label for each drug.
Receive interaction pairs with severity level, mechanism of action, clinical recommendations, and FDA evidence citations including SPL Set ID and label section.
Check drug interactions in your language of choice. All responses include severity scoring and FDA evidence citations.
curl -X POST https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check \
-H "Content-Type: application/json" \
-H "x-api-key: YOUR_API_KEY" \
-d '{
"drugs": ["metoprolol", "verapamil"]
}'import requests
response = requests.post(
"https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check",
headers={
"Content-Type": "application/json",
"x-api-key": "YOUR_API_KEY",
},
json={"drugs": ["metoprolol", "verapamil"]},
)
data = response.json()
for interaction in data.get("interactions", []):
print(f"{interaction['severity']}: {interaction['description']}")const response = await fetch(
"https://jd6095ijga.execute-api.us-east-2.amazonaws.com/v1/interactions/check",
{
method: "POST",
headers: {
"Content-Type": "application/json",
"x-api-key": "YOUR_API_KEY",
},
body: JSON.stringify({ drugs: ["metoprolol", "verapamil"] }),
}
);
const data = await response.json();
data.interactions.forEach((interaction) => {
console.log(`${interaction.severity}: ${interaction.description}`);
});Wolters Kluwer recently launched Medi-Span Expert AI, an MCP (Model Context Protocol) server that allows AI assistants and large language models to access Medi-Span drug data programmatically. This is a significant development in the drug data space, as it enables AI-powered clinical workflows to query Medi-Span's comprehensive drug database through natural language interactions.
MCP is an emerging protocol for connecting AI systems to external data sources and tools. Medi-Span Expert AI positions Wolters Kluwer at the intersection of traditional drug data and AI-assisted clinical decision support. However, access to Expert AI still requires an enterprise Medi-Span license, and the MCP server is designed primarily for AI agent workflows rather than direct REST API integration into healthcare applications.
RxLabelGuard takes a different approach. Our REST API is designed for direct integration into healthcare software -- EHR modules, pharmacy systems, telehealth platforms -- where you need structured drug interaction data returned as JSON. The API also uses AI (AWS Bedrock) internally to extract and structure interaction data from FDA labels, but the interface to your application is a standard REST API that any HTTP client can call.
If you need AI-assisted drug information queries through an MCP server within the broader Medi-Span ecosystem, Expert AI serves that use case. If you need a straightforward REST API for drug interaction checking with self-service onboarding and transparent pricing, RxLabelGuard is designed for that workflow.
Teams move from embedded pharmacy data platforms to focused APIs when their specific use case does not require the full breadth of Medi-Span.
Teams building drug interaction features for applications that do not already use Medi-Span as their pharmacy data source. When interaction checking is the only module you would license, a focused API with transparent per-request pricing is a better fit.
Telehealth startups and digital health applications adding drug interaction safety checks to prescribing or medication review workflows. A free tier allows building and testing the integration before committing to a paid plan.
Consumer-facing medication management applications that need to check interactions when patients add medications to their profile. Self-service API access with pay-per-use pricing scales with your user base.
Research teams analyzing drug interaction patterns across patient populations or formularies. API-based access with transparent pricing makes batch analysis feasible without enterprise-scale licensing commitments.
Start free. Scale as you grow. No enterprise sales cycle required.
50 requests/month, 1 API key
2,000 requests/month, 5 API keys
20,000 requests/month, unlimited keys
Common questions about switching from Medi-Span to an API-based drug interaction solution.
No. Medi-Span is a comprehensive pharmacy data infrastructure that includes drug pricing (AWP), National Drug Code (NDC) databases, Generic Product Identifier (GPI) classification, and multiple clinical screening modules. RxLabelGuard is a focused drug interaction detection API.
If your use case is specifically drug interaction checking via a programmatic API -- for example, embedding interaction alerts into a pharmacy tool, telehealth application, or medication management app -- RxLabelGuard is a suitable alternative. If you need the full Medi-Span data suite for pharmacy operations and claims processing, Medi-Span serves a broader purpose.
Medi-Span Expert AI is an MCP (Model Context Protocol) server designed for AI assistants and large language models to access Medi-Span drug data through natural language interactions. It is part of the enterprise Medi-Span ecosystem and requires a Medi-Span license.
RxLabelGuard is a standard REST API designed for direct integration into healthcare applications. You send drug names to an endpoint and receive structured interaction data as JSON. Our API uses AI internally (AWS Bedrock) to extract and structure interaction data from FDA labels, but the interface to your application is a conventional REST API that any HTTP client can call.
If you are building AI agents that need to query drug data, Expert AI via MCP may fit that workflow. If you are building healthcare software that needs drug interaction checking via HTTP, RxLabelGuard is designed for that use case with self-service onboarding and transparent pricing.
Medi-Span does not offer a public free tier or self-service trial. Access requires an enterprise licensing agreement negotiated through Wolters Kluwer sales. The evaluation process typically involves a formal vendor assessment.
RxLabelGuard offers a free Sandbox tier with 50 requests/month. No credit card is required. You can create an account, generate an API key, and start testing drug interaction queries immediately. This allows you to evaluate the API's coverage and response format before committing to a paid plan.
Yes. Many organizations use Medi-Span for its core strengths -- drug pricing (AWP), NDC data, GPI classification, and claims processing infrastructure -- while using separate, specialized services for specific clinical features like drug interaction checking.
RxLabelGuard can handle the drug interaction checking component via its REST API while your existing Medi-Span infrastructure continues to serve your pharmacy data needs. This approach allows you to use each tool for what it does best without requiring a full platform migration.
Medi-Span uses its proprietary Generic Product Identifier (GPI) system along with NDC codes for drug identification. GPI is a 14-character hierarchical classification that is widely used in pharmacy systems.
RxLabelGuard accepts drug names (brand or generic), NDC codes, and RxCUI identifiers from the National Library of Medicine's RxNorm system. Our drug resolution layer includes fuzzy matching that handles typos, abbreviations, and common name variations. If you are migrating from Medi-Span, you can typically use the same drug names or NDC codes you already have.
Create a free account and test with your critical drug pairs. No credit card, no sales call, no enterprise licensing process. Go from sign-up to first API response in minutes.
Already evaluating? Learn more about the free tier
Medical Disclaimer: This information is derived from FDA Structured Product Labeling and is provided for informational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Medi-Span and Expert AI are trademarks of Wolters Kluwer Health, Inc. RxLabelGuard is not affiliated with or endorsed by Wolters Kluwer.